HOME >> MEDICINE >> NEWS
Technology for successful aging shown at White House conference

At first glance, the blue, plastic container marked with letters representing the days of the week looks like an ordinary pill dispenser many seniors use to keep on schedule with their medication doses.

It is, indeed, a pill dispenser, with its seven individually marked compartments, but that's where its ordinariness ends. When one of the tiny compartments is opened, a signal is sent wirelessly to a computer system that records medications taken. What makes the device truly different is that it is an intelligent system that keeps track of the medications taken and knows when the senior is nearby, reminding him only when the reminder is needed and likely to be effective.

"The data generated by the MedTracker can also be used to recognize if the senior has begun to need more assistance with their medication, and may even be helpful in identifying early memory changes" says Tamara Hayes, Ph.D., assistant professor of biomedical engineering at Oregon Health & Science University's OGI School of Science and Engineering, and lead investigator on the MedTracker project.

The intelligent MedTracker pill box is one of a handful of innovative devices OHSU researchers are developing to unobtrusively monitor how seniors go about their day-to-day lives in their homes. The technologies are an important part of the research being conducted within the National Institutes of Health-funded center ORCATECH, or Oregon Roybal Center for Aging & Technology.

ORCATECH, a collaboration of academic, industry and community partners, is researching and developing technology to assess how seniors function in their home environment. The goal is to help them maintain their independence, and optimize their health and quality of life, by discretely collecting data for intelligent computing systems that can detect changes in health long before they would affect the quality of life of the elders and their caregivers. The ultimate goal is for the integrated intelligen
'"/>

Contact: Jonathan Modie
modiej@ohsu.edu
503-494-8231
Oregon Health & Science University
13-Dec-2005


Page: 1 2 3

Related medicine news :

1. Stevens Roundtable: Health, Technology & Society, July 11
2. Panbio files first patent application for Homogenous Assay Technology
3. Telebriefing on NCIs Network of Clinical Proteomic Technology Assessment for Cancer Teams
4. NCI creates network of Clinical Proteomic Technology Centers for cancer research
5. Stevens Institute of Technology Roundtable
6. Technology to improve learning for visually-impaired children
7. Technology to improve care at the bedside and beyond
8. Technology helps disabled kids find their voice
9. UK Select Committee on Science and Technology does not appropriately scrutinize British science
10. Lighting of the future among topics at BGSU Emerging Technology Forum
11. Technology helps Stanford shed new light on coronary bypass surgery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Technology for successful aging shown White House conference

(Date:5/21/2013)... DISCcert has served the training industry ... 17 DISC applications at the July 25 & 26th ... The July 25 & 26th DISC certification in San ... applying DISC. The time-tested, proven support materials will include ... DISC training materials ; worksheets, handouts, learning activities, ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... to protecting the rights of victims injured by defective ... Journal of Bone & Joint Surgery on May 15, ... can be used to identify complications that occur in ... any symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... OR (PRWEB) May 21, 2013 Phoseon ... systems at the 20th Annual IMI European Ink ... a proven market leader, Phoseon continues to invest in ... accelerating the adoption of UV LED curing in printing ... product families on the market offering both air cooled ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
(Date:5/21/2013)... Md. , May 21, 2013 ... disposable drug-free consumer electronic devices, announced that CEO, ... presenting today to the FDA,s Medical Advisory Committee, ... the company,s products for over the counter sales. ... FDA developed its medical device classification schema," Whelan ...
(Date:5/21/2013)... 21, 2013 Reportlinker.com announces that ... in its catalogue:   ... Optical Coherence Tomography (OCT) ... OBJECTIVES   BCC,s ... offer synopsis of the current and future ...
(Date:5/21/2013)... TARRYTOWN, N.Y. , May 21, 2013 /PRNewswire/ ... Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ... positive Phase 2a study results of dupilumab (SAR231893/REGN668) in ... monoclonal antibody targeting the alpha subunit of the interleukin ... IL-4 and IL-13, drivers of Th2 (Type 2 helper ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7
Cached News: